Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 8/20 | 0.35 |
| ▸ | PDE4B | Q07343 | 8/20 | 0.35 |
| ▸ | PDE4C | Q08493 | 8/20 | 0.35 |
| ▸ | PDE4D | Q08499 | 8/20 | 0.35 |
| ▸ | STING1 | Q86WV6 | 8/20 | 0.35 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.33 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16158819 | 0.82 | STING1 (0.33) | PDE4APDE4BPDE4CPDE4DSTING1 | |
| SCHEMBL16158841 | 0.80 | PDE4A (0.39) | PDE4APDE4BPDE4CPDE4DSTING1 | |
| SCHEMBL10150520 | 0.79 | DHFR (0.39) | — | |
| SCHEMBL16158818 | 0.78 | TDP1 (0.34) | PDE4APDE4BPDE4CPDE4DSTING1 | |
| SCHEMBL16158835 | 0.77 | RXFP1 (0.33) | PDE4APDE4BPDE4CPDE4DSTING1 | |
| SCHEMBL17826624 | 0.73 | DHFR (0.53) | PDE4APDE4BPDE4CPDE4DSTING1 | |
| SCHEMBL17826380 | 0.72 | PDE4A (0.40) | PDE4APDE4BPDE4CPDE4DSTING1 | |
| SCHEMBL17826621 | 0.67 | LMNA (0.47) | PDE4APDE4BPDE4CPDE4DSTING1 | |
| SCHEMBL18016510 | 0.66 | CHEK1 (0.34) | LMNA | |
| SCHEMBL18016507 | 0.65 | ADORA3 (0.36) | LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9365605-B2 | Cyclic nucleotide analogs | ALIOS BIOPHARMA, INC. (US) | 2016-06-14 | — | — | US | disclosed |
| US-20140303108-A1 | CYCLIC NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA, INC. | 2014-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140303108-A1 | CYCLIC NUCLEOTIDE ANALOGS | NT5C2, NTPCR, PNP | PDE4A 22/4885PDE4B 28/4885PDE4C 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.